Amivantamab vs real-world (RW) therapy in Japanese patients with advanced non-small cell lung cancer (aNSCLC) epidermal growth factor receptor (EGFR) exon-20 insertion mutation (E20i)

被引：0
|
作者：
Kim, T. M. [1 ]
Girard, N. [2 ]
Low, G. K. M. [3 ]
Zhuo, J. [4 ]
Yu, D. Y. [5 ]
Yang, Y. [4 ]
Murota, M. [6 ]
Lim, C. [7 ]
Kleinman, N. J. [8 ]
Cho, B. C. [9 ]
机构：
[1] Seoul Natl Univ Hosp, Hemato Oncol, Seoul, South Korea
[2] Inst Curie, Thorax Inst, Paris, France
[3] Janssen Asia Pacific, Med Affairs, Singapore, Singapore
[4] Janssen China, Res & Dev, Shanghai, Peoples R China
[5] Janssen Asia Pacific, Real World Evidence, Singapore, Singapore
[6] Janssen Res & Dev, Med Affair Operat, Global Dev, Tokyo, Japan
[7] IQVIA Solut Asia Pte Ltd, Real World Solut, Singapore, Singapore
[8] IQVIA Hong Kong, Real World Solut, Hong Kong, Peoples R China
[9] Yonsei Univ, Coll Med, Yonsei Canc Ctr, Dept Med Oncol, Seoul, South Korea
来源：
ANNALS OF ONCOLOGY | 2022年 / 33卷 / 07期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
1109p
引用
收藏
页码：S1058 / S1058
页数：1
相关论文
共 50 条
  • [1] Amivantamab vs real-world (RW) therapies for advanced non-small cell lung cancer (aNSCLC) with epidermal growth factor receptor (EGFR) exon 20 insertion mutation (E20i) in Japan
    Okahisa, M.
    Udagawa, H.
    Matsumoto, S.
    Kato, T.
    Yokouchi, H.
    Furuya, N.
    Kanemaru, R.
    Toyozawa, R.
    Nishiyama, A.
    Ohashi, K.
    Miyamoto, S.
    Nishino, K.
    Oi, H.
    Low, G. K. M.
    Zhuo, J.
    Yu, D. Young
    Yang, Y.
    Lim, C.
    Kleinman, N. J.
    Goto, K.
    ANNALS OF ONCOLOGY, 2022, 33 (07) : S1061 - S1061
  • [2] Effectiveness and safety of amivantamab in EGFR exon 20 insertion (E20I) mutations in non-small cell lung cancer (NSCLC)
    Choi, Dae-Ho
    Jung, Hyun Ae
    Park, Sehhoon
    Sun, Jong -Mu
    Ahn, Jin Seok
    Ahn, Myung-Ju
    Lee, Se-Hoon
    TRANSLATIONAL LUNG CANCER RESEARCH, 2023, 12 (12) : 2448 - 2459
  • [3] Real-world frequency of non-small cell lung cancer with epidermal growth factor receptor (EGFR) exon 20 insertion (Exon20ins) mutations by site of insertion
    Viteri, S.
    Bauml, J. M.
    Bazhenova, L.
    Ou, S-H. I.
    Girard, N.
    Schaffer, M.
    Rose, J.
    Curtin, J.
    Karkera, J.
    Mahadevia, P.
    Minchom, A. R.
    JOURNAL OF THORACIC ONCOLOGY, 2021, 16 (04) : S699 - S699
  • [4] AMIVANTAMAB VERSUS REAL-WORLD CLINICAL PRACTICE IN EUROPE AND THE US FOR PATIENTS WITH ADVANCED NON-SMALL CELL LUNG CANCER WITH ACTIVATING EPIDERMAL GROWTH FACTOR RECEPTOR EXON 20 INSERTION MUTATIONS
    Chouaid, C.
    Girard, N.
    Kron, A.
    Scheffler, M.
    Knott, C.
    Bosquet, L.
    Trigo, J.
    Viteri, S.
    Sebastian, M.
    Popat, S.
    Rahhali, N.
    Toueg, R.
    Rodrigues, B.
    Diels, J.
    Schioppa, C. A.
    Cabrieto, J.
    Sermon, J.
    Perualila, N. J.
    Erdmann, N.
    Mielke, J.
    Nematian-Samani, M.
    Pfaira, I
    Martin-Fernandez, C.
    Mahadevia, P.
    Li, T.
    Pick-Lauer, C.
    Adamczyk, A.
    Penton, J.
    Wolf, J.
    VALUE IN HEALTH, 2022, 25 (12) : S32 - S32
  • [5] Targeting EGFR Exon 20 Insertion Mutation in Non-small cell Lung Cancer: Amivantamab and Mobocertinib
    Russell, Molly C.
    Garelli, Alyssa M.
    Reeves, David J.
    ANNALS OF PHARMACOTHERAPY, 2023, 57 (02) : 198 - 206
  • [6] Amivantamab versus alternative real-world anti-cancer therapies in patients with advanced non-small cell lung cancer with epidermal growth factor receptor exon 20 insertion mutations in the US and Europe
    Girard, N.
    Wolf, J.
    Kim, T. M.
    Leighl, N.
    Knott, C.
    Li, T.
    Cabrieto, J.
    Diels, J.
    Sermon, J.
    Mahadevia, P.
    Schioppa, C. A.
    Sabari, J.
    JOURNAL OF THORACIC ONCOLOGY, 2023, 18 (04) : S56 - S56
  • [7] Amivantamab compared with European, real-world (RW) standard of care (SoC) in adults with advanced non-small cell lung cancer (NSCLC) with activating epidermal growth factor receptor (EGFR) exon 20 insertion mutations (exon20ins), after failure of platinum-based therapy
    Girard, N.
    Popat, S.
    Rahhali, N.
    Rodrigues, B.
    Schioppa, C. A.
    Pick-Lauer, C.
    Adamczyk, A.
    Sermon, J.
    Diels, J.
    Penton, J.
    Thomas, M.
    ANNALS OF ONCOLOGY, 2022, 33 (07) : S1062 - S1062
  • [8] Epidermal growth factor receptor mutation (EGFRm) testing in advanced non-small cell lung cancer (aNSCLC) in a real-world setting
    Subramanian, J.
    Gregg, J.
    Wang, H.
    Sun, P.
    Yu, B.
    Shenolikar, R.
    Chau, M.
    Taylor, A.
    Leighl, N.
    ANNALS OF ONCOLOGY, 2020, 31 : S888 - S889
  • [9] Epidermal growth factor receptor exon 20 insertion variants in non-small cell lung cancer patients
    Malapelle, Umberto
    Pilotto, Sara
    Reale, Maria Lucia
    Passiglia, Francesco
    Pisapia, Pasquale
    Pepe, Francesco
    Belluomini, Lorenzo
    Galetta, Domenico
    Cortinovis, Diego
    Tiseo, Marcello
    Passaro, Antonio
    Seminati, Davide
    Pagni, Fabio
    Parra, Hector Soto
    Migliorino, Maria Rita
    Rocco, Danilo
    Troncone, Giancarlo
    Novello, Silvia
    CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY, 2022, 169
  • [10] Amivantamab for the treatment of EGFR exon 20 insertion mutant non-small cell lung cancer
    Vyse, Simon
    Huang, Paul H.
    EXPERT REVIEW OF ANTICANCER THERAPY, 2022, 22 (01) : 3 - 16
12345